Neuberger Berman Group
SRNE

Neuberger Berman Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Neuberger Berman Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-44,200
Closed -$566K – 1764
2014
Q1 		$566K Buy
+44,200
New +$489K ﹤0.01% 1318

Other funds holding SRNE

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.39% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Neuberger Berman Group's SRNE Position: Q2 2014 in Review

Neuberger Berman Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2014, closing a stake of 44,200 shares — an estimated $566K sold.

Neuberger Berman Group first reported a position in SRNE in Q1 2014 and held it in 1 quarter. The position peaked at $566K in Q1 2014. 37 funds tracked by Wall St. Rank hold SRNE as of Q2 2014.

  • Neuberger Berman Group reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Neuberger Berman Group sold 44,200 Sorrento Therapeutics, Inc. shares in Q2 2014, an estimated $566K.
  • Neuberger Berman Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Neuberger Berman Group's Sorrento Therapeutics, Inc. position peaked at $566K in Q1 2014.
  • 37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2014.

Based on Neuberger Berman Group's 13F filing for Q2 2014, filed 5 Aug 2014.